Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 16/20 | 1.00 |
| ▸ | LCK | P06239 | 3/20 | 0.71 |
| ▸ | CSF1R | P07333 | 2/20 | 0.70 |
| ▸ | KDR | P35968 | 1/20 | 0.70 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.70 |
| ▸ | HTR1D | P28221 | 3/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.64 |
| ▸ | HTR1B | P28222 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14463562 | 0.87 | MAPK14 (0.77) | MAPK14LCKCSF1RKDRMAP2K1 | |
| SCHEMBL14078303 | 0.86 | MAPK14 (0.86) | MAPK14LCKCSF1RKDRMAP2K1 | |
| SCHEMBL6485976 | 0.83 | MAPK14 (1.00) | MAPK14LCKCSF1RHTR1DSLC6A4 | |
| SCHEMBL5124614 | 0.82 | MAPK14 (1.00) | MAPK14LCKCSF1RKDRMAP2K1 | |
| SCHEMBL4855098 | 0.82 | MAPK14 (0.77) | MAPK14LCKCSF1RKDRMAP2K1 | |
| SCHEMBL7801646 | 0.81 | HTR1D (0.87) | MAPK14LCKCSF1RKDRMAP2K1 | |
| SCHEMBL4858353 | 0.81 | MAPK14 (1.00) | MAPK14LCKCSF1RKDRMAP2K1 | |
| SCHEMBL4703449 | 0.80 | MAPK14 (0.67) | MAPK14LCKHTR1DHTR1BHTR2A | |
| SCHEMBL4700916 | 0.80 | MAPK14 (0.67) | MAPK14LCKCSF1RKDRHTR1D | |
| SCHEMBL6605456 | 0.80 | MAPK14 (0.69) | MAPK14LCKCSF1RKDRMAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050065195-A1 | Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2005-03-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065195-A1 | Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors | MAPK3, MAPK1, MAPKAPK3 | MAPK14 7/4885LCK 56/4885CSF1R 2373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.